deciphera20pharmaceuticals2c20inc.  (DCPH) - nasdaqgs   Revenue / EPS Summary *      Fiscal Quarter 2023 (Fiscal Year) 2022 (Fiscal Year) 2021 (Fiscal Year) March          Revenue $33,445(t) $29,223(t) $25,156(t)    EPS -0.6 (3/31/2023) -0.8 (3/31/2022) -1.06 (3/31/2021)    Dividends N/A N/A N/A June          Revenue $38,304(t) $32,494(t) $23,573(t)    EPS -0.57 (6/30/2023) -0.51 (6/30/2022) -1.22 (6/30/2021)    Dividends N/A N/A N/A September          Revenue $43,313(t) $35,974(t) $23,220(t)    EPS -0.58 (9/30/2023) -0.51 (9/30/2022) -1.37 (9/30/2021)    Dividends N/A N/A N/A December  (FYE)          Revenue $48,294(t) $36,345(t) $24,199(t)    EPS -0.54 (12/31/2023) -0.55 (12/31/2022) -1.51 (12/31/2021)    Dividends N/A N/A N/A Totals          Revenue $163,356(t) $134,036(t) $96,148(t)    EPS -2.29 -2.37 -5.16    Dividends N/A N/A N/A    Previous 3 Years
©2024, EDGAR®Online LLC, a subsidiary of OTC Markets Group. EDGAR® and SEC® are trademarks of the U.S. Securities and Exchange Commission. OTC Markets Group Inc.'s products and services are not affiliated with or approved by the U.S. Securities and Exchange Commission.